Do GCKR rs1260326 and MBOAT7 rs641738 variants increase NAFLD risk and ALT levels?

Genetic evidence strongly supports the association between specific variants in the GCKR and MBOAT7 genes and an increased risk of nonalcoholic fatty liver disease (NAFLD), as well as elevated markers of liver injury.

Genetic and clinical evidence

Large-scale genome-wide association studies (GWAS) and meta-analyses have consistently identified these loci as significant drivers of liver health:

• GCKR rs1260326: The T allele of this variant is a well-established risk factor for NAFLD, with odds ratios (OR) typically ranging from 1.32 to 1.65. Carriers of this variant often exhibit higher liver fat content (measured via MRI-PDFF) and significantly elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
• MBOAT7 rs641738: The T allele at this locus is strongly linked to increased hepatic fat accumulation and higher circulating ALT. This variant is not only associated with the presence of NAFLD but also with its progression toward more severe forms, including fibrosis and cirrhosis, across both adult and pediatric populations.

Mechanistic explanations

These genetic variants increase liver risk through distinct biological pathways that disrupt hepatic lipid homeostasis:

• GCKR (Glucokinase Regulator): The rs1260326 variant increases the activity of glucokinase in the liver. This enhances the conversion of glucose into fatty acids (de novo lipogenesis), which directly increases hepatic steatosis and elevates plasma triglyceride levels.
• MBOAT7 (Membrane Bound O-Acyltransferase Domain Containing 7): This enzyme is responsible for incorporating arachidonic acid into phospholipids. The rs641738 variant reduces MBOAT7 expression, leading to an accumulation of lysophosphatidylinositol (LPI) and altered cell membrane composition. This biochemical imbalance triggers lysosomal dysfunction and activates pro-fibrotic pathways (such as the TAZ-IHH axis), causing hepatocyte injury and the subsequent release of ALT into the bloodstream.

Clinical implications

For individuals carrying these variants, the genetic predisposition facilitates both the accumulation of fat (steatosis) and the cellular damage (inflammation/injury) that characterizes disease progression. Monitoring liver enzymes like ALT serves as a clinically relevant method for tracking the hepatocellular injury mediated by these specific metabolic pathways.

Bottom line

The GCKR rs1260326 and MBOAT7 rs641738 variants are scientifically validated markers for increased NAFLD risk and higher ALT levels. They drive liver injury by promoting excessive fat production and disrupting phospholipid remodeling, respectively.